Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2023-04-09 Capital/Financing Update
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi to streamline nirsevimab contractual arrangements
Capital/Financing Update Classification · 99% confidence The document discusses contractual changes regarding the drug nirsevimab, specifically a new royalty agreement with Sanofi and the termination of a participation agreement with AstraZeneca. It details financial considerations (payments, royalty rates) related to these business restructuring activities. This content relates to corporate financing, asset restructuring, and business operations, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific announcement about a material business transaction that affects future revenue streams and capital structure. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it involves restructuring financial agreements and obligations. It is not a general regulatory filing (RNS) because it is highly specific to financing/contractual changes.
2023-04-09 English
Sobi renodlar avtalet för nirsevimab
M&A Activity Classification · 99% confidence The document is a press release announcing a simplification and streamlining of the financial terms related to the nirsevimab agreement, involving new royalty agreements with Sanofi and termination of a profit-sharing agreement with AstraZeneca. It details financial considerations (USD payments, royalty percentages) and references the company's 2022 Annual and Sustainability Report. The text concludes with a statement that the information is being made public under the EU Market Abuse Regulation and specifies the release date and time (April 9, 2023). This structure strongly indicates a formal corporate announcement regarding a significant business/financial event, which is typically classified as an Earnings Release (ER) if it contains key financial updates, or a Regulatory Filing (RNS) if it's a general disclosure. Since this is a specific announcement about contract restructuring and financial implications, and not a full quarterly report (IR) or a general market notice (RNS), it fits best as an Earnings Release (ER) or a Capital/Financing Update (CAP) due to the focus on revenue/cost structures. Given the context of major financial restructuring and the announcement of specific financial terms, ER is often used for significant financial news outside of standard quarterly reporting periods. However, since it is a specific, material corporate action announcement that doesn't fit perfectly into ER (which usually covers P&L results), and it is a formal disclosure under MAR, the most appropriate general category for material, non-standard announcements is often RNS, or if it relates to financing/capital structure changes, CAP. Since it is a major change in revenue/cost structure related to a product, and it is a formal disclosure, I will classify it as a Regulatory Filing (RNS) as it is a broad category for material announcements not covered elsewhere, although it has strong elements of a financial update. Upon review of the definitions, it is a specific corporate action announcement, not a standard ER, IR, or CAP. RNS serves as the best fit for material, non-standard regulatory disclosures.
2023-04-09 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-03 Swedish
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)". It details the date, time, location, procedures for participation (in person and by postal voting), and the proposed agenda for the Annual General Meeting (AGM). The agenda items cover the election of the chairman, board members, auditors, approval of remuneration, and resolutions on incentive programs, which are all standard components of an AGM notice/materials. This directly corresponds to the definition of AGM Information (AGM-R). Although it contains elements that might overlap with remuneration (DEF 14A) or governance (CGR), the primary purpose and structure are that of the official meeting summons and associated materials.
2023-03-30 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)" which translates to "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)". The text details the date, location, procedures for participation (in person and by postal vote), the proposed agenda (including election of board members, approval of remuneration, and proposals regarding incentive programs), and specific proposals related to the AGM. This content is characteristic of a formal notice and materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2023-03-30 Swedish
Fas 3-programmet DISSOLVE med SEL-212 vid kronisk gikt uppnår primära effektmått
Earnings Release Classification · 99% confidence The document is a press release dated March 21, 2023, announcing positive topline results from Phase 3 clinical trials (DISSOLVE I and II) for a drug candidate (SEL-212) used to treat chronic refractory gout. It details efficacy endpoints, safety profiles, and future regulatory plans (US submission in H1 2024). This content—announcing key financial/clinical trial outcomes for a reporting period—is characteristic of an Earnings Release (ER) or a general announcement of significant corporate news. Since it focuses specifically on clinical trial results and not comprehensive financial performance for a fiscal period (which would suggest 10-K or IR), and it is a direct announcement of results rather than a presentation (IP) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these announcements often accompany or precede formal quarterly reports. It is not a Report Publication Announcement (RPA) because it contains the substantive results themselves, not just a notice that a report is available. It is too detailed for a simple Regulatory Filing (RNS). FY 2023
2023-03-21 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.